Rate My Professor Patrick Gunning

Gunning's research specializations encompass small molecule therapeutics, targeted protein degradation, covalent drug discovery, non-cysteine targeted covalent therapeutics, GPCR-targeted therapeutics, and peptidomimetics. He is recognized as the founder of six biotechnology companies and a contract research organization, with a strong emphasis on commercialization and entrepreneurship. Current grants include Medical Research Council funding for the Casan Therapeutics project on the development of selective and covalent HDAC inhibitors (2026-2027) and for lysine-targeting kinase inhibitors for lung carcinomas (2025-2026). His scholarly impact is evidenced by over 7,000 citations on Google Scholar. Key publications feature 'Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts' (Zhang et al., 2012, 404 citations), 'Advances in covalent kinase inhibitors' (Abdeldayem et al., 2020, 341 citations), 'Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer' (Wingelhofer et al., 2018, 289 citations), 'An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects' (Siddiquee et al., 2007, 240 citations), and 'A novel small-molecule disrupts Stat3 SH2 domain–phosphotyrosine interactions and Stat3-dependent tumor processes' (Zhang et al., 2010, 235 citations). Gunning was honored as University of Glasgow Young Alumnus of the Year in 2010.